Crossmark

Randomized, double-blind, placebo-controlled study of oral duloxetine in prevention of acute pain syndrome in breast cancer patients receiving paclitaxel (DOPA study)

Crossref DOI link: https://doi.org/10.1186/s13063-026-09673-9

Published Online: 2026-04-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Banotra, Jahnavi

Shetty, Vrajesh Veenadhar

Bakhshi, Sameer

Srivastava, Achal Kumar

Gupta, Sudeep

Kumar, Akash

Bhargava, Prabhat

Gangadhar, Bharath

Vasudeva, Payal

Pallavi, Kriti

Bhati, Kamesh

Singh, Shlok

Verma, Neha

Divakar, Mohit Kumar

Baskarane, Hemavathi

Batra, Atul https://orcid.org/0000-0002-1934-8408
Funding

Funding for this research was provided by:

All-India Institute of Medical Sciences (No.F.5-59/IRG/2010/RS)
License Information

Text and Data Mining valid from 2026-04-18

Version of Record valid from 2026-05-29
More Information

Article History

Received: 3 September 2025

Accepted: 22 March 2026

First Online: 18 April 2026

Declarations

:

: The study protocol has been reviewed and approved by the Institutional Ethics Committee of the All India Institute of Medical Sciences, New Delhi; Ref. No.: AIIMSA1239/05.04.2024.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below